There is more detailed and specific guidance on the BSR site here.

RWT

RWT have created an excellent video presentation which is available under the Patient information section on this page. Although it is aimed at patients we can take some advice from it too. This video is to be published and has been highly rated widely.

Key slides and Summary Points as I see it are below:

1. If patients are well – CONTINUE Meds.
2. If patient is unwell then Follow Advice in slide 1 below.
3. The prevailing government guidance on social distancing, shielding etc should be followed.
4. If asked/or need to identify those at high risk – use slide 2 below. This is adapted from national guidance.

Dr Nick Barkham, Consultant Rheumatologist, RWT has advised us further regarding steroid injections for Rheumatology patients. Please consider depot steroids when assessing risk for patients.

“I would agree that depot steroid injection is 2 points for 3 months”

Dr N Barkham, Rheumatologist
Slide 1
Slide 2

MPFT

MPFT have issued a letter. Which pretty much echos what is above, except:
“Although guidance regarding COVID-19 says sulfasalazine can be continued, we recommend stopping it (until you feel well) in case you are developing another infection.”
They are also suggesting reviewing the need to start new medication. However, I feel that would be best managed by the rheumatology team.

UHDB

UHDB have put out letters which are available in the Briefings section on this site. They seem to follow national guidance on the matter.

UHNM

Not seen anything by UHNM yet. Let me know if you have.